Literature DB >> 12957491

Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.

Elyse S Kemmerer1, Timothy J Desmond, Roger L Albin, Michael R Kilbourn, Kirk A Frey.   

Abstract

There is controversy over potential effects of dopaminergic replacement therapies on the partially lesioned nigrostriatal dopaminergic projection. We evaluated indirect (levodopa, L-DOPA) versus direct (pramipexole, PRA) dopaminergic treatment effects on nigrostriatal lesion severity as measured with vesicular monoamine transporter type-2 (VMAT2) binding. Prior studies have shown that striatal VMAT2 density provides an objective estimate of dopaminergic neuronal integrity, without confounding effects of compensatory regulation. Partial unilateral median forebrain bundle lesions were made by injection of 6-hydroxydopamine in adult male Sprague-Dawley rats. Lesion severity was estimated using rotational behavior after injections of apomorphine and amphetamine. Rats were ranked and matched in pairs by rotation and assigned to receive either PRA (1 mg/kg/day) or L-DOPA/benserazide (100/25 mg/kg/day) ip via osmotic pump. After 4 weeks of drug treatment, in vitro autoradiography was performed with [(3)H]methoxytetrabenazine to measure striatal VMAT2 binding density. Lesion-to-intact VMAT2 density correlated with rotation in both treatment groups. There was no treatment effect on VMAT2 expression in the partially lesioned striatum and thus no differential effect of indirect versus direct dopamimetic treatment on nigrostriatal integrity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957491     DOI: 10.1016/s0014-4886(03)00096-7

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  10 in total

1.  Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.

Authors:  Leigh Christopher; Connie Marras; Sarah Duff-Canning; Yuko Koshimori; Robert Chen; Isabelle Boileau; Barbara Segura; Oury Monchi; Anthony E Lang; Pablo Rusjan; Sylvain Houle; Antonio P Strafella
Journal:  Brain       Date:  2013-12-12       Impact factor: 13.501

2.  The role of pramipexole in a severe Parkinson's disease model in mice.

Authors:  Seham Gad Elhak; Abdel Aziz Ghanem; Hasan Abdelghaffar; Sahar Eldakroury; Dina Eltantawy; Sara Eldosouky; Mohamed Salama
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

3.  Dampening of Serotonergic System through 5HT1A Receptors is a Promising Target for Treatment of Levodopa Induced Motor Problems.

Authors:  Javad Mahmoudi; Mehdi Farhoudi; Siamak Reyhani-Rad; Saeed Sadigh-Eteghad
Journal:  Adv Pharm Bull       Date:  2013-08-20

4.  Dependence of cardiac 11C-meta-hydroxyephedrine retention on norepinephrine transporter density.

Authors:  David M Raffel; Wei Chen; Phillip S Sherman; David L Gildersleeve; Yong-Woon Jung
Journal:  J Nucl Med       Date:  2006-09       Impact factor: 10.057

5.  Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats.

Authors:  Reena Haobam; Debasmita Tripathy; Navneet A Kaidery; Kochupurackal P Mohanakumar
Journal:  Rejuvenation Res       Date:  2015-04       Impact factor: 4.663

Review 6.  Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.

Authors:  Nicolaas I Bohnen; Kirk A Frey
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

7.  Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.

Authors:  Vesna Sossi; Katherine Dinelle; Michael Schulzer; Edwin Mak; Doris J Doudet; Raúl de la Fuente-Fernández
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-10       Impact factor: 9.236

8.  Simple, rapid and reliable preparation of [¹¹C]-(+)-α-DTBZ of high quality for routine applications.

Authors:  Jinming Zhang; Xiaojun Zhang; Yungang Li; Jiahe Tian
Journal:  Molecules       Date:  2012-06-01       Impact factor: 4.411

9.  Diagnostic value of striatal 18F-FP-DTBZ PET in Parkinson's disease.

Authors:  Xiu-Lin Liu; Shu-Ying Liu; Olivier Barret; Gilles D Tamagnan; Hong-Wen Qiao; Tian-Bin Song; Jie Lu; Piu Chan
Journal:  Front Aging Neurosci       Date:  2022-07-22       Impact factor: 5.702

10.  Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.

Authors:  Jeffrey N Joyce; Cheryl Woolsey; Han Ryoo; Sabine Borwege; Diane Hagner
Journal:  BMC Biol       Date:  2004-10-11       Impact factor: 7.431

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.